13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • BR.31

    Acronym: 

    BR.31

    ACTRN/NCT /ethics: 

    ACTRN12615000323527NCT02273375

    Scientific title: 

    A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase III Tumour Stream Lung -Non Small Cell
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2014-10-09
    Molecular Target Anticipated End Date 2025-01-01
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Lung -Non Small Cell
    Cancer Stage All stages
    Anticipated Start Date 2014-10-09
    Anticipated End Date 2025-01-01

    Trial Summary

    The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

    Lay Summary

    A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer

    Sponsor / Cooperative group

    Canadian Cancer Trials Group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Chris Karapedis Recruiting
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Brown Recruiting